Connect Biopharma Holdings Limited
CNTB
$0.7901
-$0.0099-1.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 74.84% | 74.02% | 73.72% | 59.55% | 49.42% |
| Total Depreciation and Amortization | -8.33% | -24.45% | -35.78% | -33.91% | -32.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.44% | 8.35% | -31.10% | -46.92% | -59.23% |
| Change in Net Operating Assets | -257.24% | -336.52% | -868.37% | -39.29% | 43.13% |
| Cash from Operations | 50.54% | 63.16% | 70.69% | 61.59% | 54.76% |
| Capital Expenditure | -825.93% | 68.85% | 92.60% | 95.93% | 98.21% |
| Sale of Property, Plant, and Equipment | -- | 0.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.60% | -47.84% | 153.33% | 297.94% | 185.83% |
| Cash from Investing | -104.60% | -47.14% | 195.48% | 276.81% | 181.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 98.62% | 98.62% | 99.59% | 100.00% |
| Issuance of Common Stock | 404.44% | 273.67% | 146.06% | -79.70% | -94.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 404.44% | 278.46% | 150.52% | 151.49% | 154.74% |
| Foreign Exchange rate Adjustments | -4.75% | 91.72% | 96.23% | 91.58% | -2,517.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.68% | 101.72% | 136.32% | 120.14% | 113.52% |